Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany
Crossref DOI link: https://doi.org/10.1007/s40744-020-00204-9
Published Online: 2020-04-17
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Krüger, Klaus
Burmester, Gerd Rüdiger
Wassenberg, Siegfried
Thomas, Matthias H.
Funding for this research was provided by:
Meso Scale Diagnostics
Article History
Received: 14 February 2020
First Online: 17 April 2020